(Q39663316)

13 September 2017

title

Synergistic anti-tumor effects between oncolytic vaccinia virus and paclitaxel are mediated by the IFN response and HMGB1. (English)

1 reference

13 September 2017

1 reference

1 reference

vaccinia virus

1 reference

B Huang

1

1 reference

13 September 2017

R Sikorski

series ordinal

2

1 reference

13 September 2017

D H Kirn

series ordinal

3

1 reference

13 September 2017

S H Thorne

series ordinal

4

1 reference

13 September 2017

publication date

26 August 2010

1 reference

13 September 2017

1 reference

13 September 2017

volume

18

1 reference

13 September 2017

issue

2

1 reference

13 September 2017

page(s)

164-172

1 reference

Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer

13 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Efficacy of oncolytic herpesvirus NV1020 can be enhanced by combination with chemotherapeutics in colon carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Paclitaxel and vincristine potentiate adenoviral oncolysis that is associated with cell cycle and apoptosis modulation, whereas they differentially affect the viral life cycle in non-small-cell lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

The formation and function of extracellular enveloped vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Infection with vaccinia virus alters regulation of cell cycle progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Vaccinia virus cores are transported on microtubules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Targeting HMGB1 in inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Reversing established sepsis with antagonists of endogenous high-mobility group box 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Heparan sulfate and control of endothelial cell proliferation: increased synthesis during the S phase of the cell cycle and inhibition of thymidine incorporation induced by ortho-nitrophenyl-beta-D-xylose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

High-mobility group box 1 and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

HMGB1: a two-headed signal regulating tumor progression and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

The role of autophagy in sensitizing malignant glioma cells to radiation therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

inferred from DOI database lookup

7 January 2021

based on heuristic

A27L protein mediates vaccinia virus interaction with cell surface heparan sulfate

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

inferred from DOI database lookup

7 January 2021

based on heuristic

Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain.

1 reference

https://api.crossref.org/works/10.1038%2FGT.2010.121

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/GT.2010.121

1 reference

13 September 2017

1 reference